Vascular endothelial growth factor is essential for corpus luteum angiogenesis (original) (raw)

References

1. Bassett, D.E.L. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am. J. Anat. 73, 251–278 (1943).
   Article Google Scholar
2. Gospodarowicz, D. & Takral, T.K. Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc. Natl. Acad. Sci. USA 75, 847–851 (1978).
   Article CAS PubMed PubMed Central Google Scholar
3. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4–25(1997).
   Article CAS PubMed Google Scholar
4. Phillips, H.S., Hains, J., Leung, D.W. & Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127, 965–967 (1990).
   Article CAS PubMed Google Scholar
5. Kamat, B.R., Brown, L.F., Manseau, E.J., Senger, D.R. & Dvorak, H.F. Expression of vascular permeability factor/vascular endothelial growth factor by human granu-losa and theca lutein cells: Role in corpus luteum development. Am. J. Pathol. 146, 157–165(1995).
6. Shweiki, D., Itin, A., Neufeld C., Gitay-Goren, H. & Keshet, E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis. J. Clin. Invest. 91, 2235–2243 (1993).
   Article CAS PubMed PubMed Central Google Scholar
7. Gospodarowicz, D., Cheng, J., Lui, G.M., Baird, A. & Bohlen, P. Corpus luteum angiogenesis factor is related to fibroblast growth factor. Endocrinology 117, 2283–2290 (1985).
   Article Google Scholar
8. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277, 55–60 (1997).
   Article CAS PubMed Google Scholar
9. de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991 (1992).
   Article CAS PubMed Google Scholar
10. Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457–10461 (1995).
    Article CAS PubMed PubMed Central Google Scholar
11. Kendall, R.L., Wang, G. & Thomas, K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324–328 (1996).
    CAS Google Scholar
12. Davis-Smyth, T., Chen, H., Park, J., Presta, L.G. & Ferrara, N. The second im-munoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919–4927 (1996).
    Article CAS PubMed PubMed Central Google Scholar
13. Gates, A.H. Maximizing yield and developmental uniformity of eggs, in Methods in Mammalian Embryology. (ed. Daniels, J.) 46–76 (Freeman, San Francisco, 1971).
    Google Scholar
14. Rothchild, I. The regulation of the mammalian corpus luteum. Rec. Prog. Horm. Res. 37, 183–298(1981).
15. Park, J.E., Chen, H.H., Winer, J., Houck, K.A. & Ferrara, N. Placenta growth factor: Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646–25654(1994).
16. Cao, Y. et al. Heterodimers of placenta growth factor/vascular endothelial growth factor: Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR J. Biol. Chem. 271, 3154–3162 (1996).
    Article CAS PubMed Google Scholar
17. Smith, L.E. et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706–1709 (1997).
    Article CAS PubMed Google Scholar
18. Goldziher, J.W. & Green, J.A. The polycystic ovary. I. Clinical and histologic features. J. Clin. Endocrinol. Metab. 22, 325–332 (1962).
    Google Scholar
19. Engel, T., Jewelewicz, R., Dyrenfurth, I., Speroff, L. & Vande Wiele, R.L. Ovarian hy-perstimulation syndrome: Report of one case with notes on pathogenesis and treatment. Am. J. Obstet. Cynecol. 112, 1052–1057 (1972).
    Article CAS Google Scholar
20. McClure, N. et al. Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344, 235–269 (1994).
    Article CAS PubMed Google Scholar
21. Murthy, Y.S., Arronet, G.H. & Pareck, M.C. Luteal phase inadequacy. Obstet. Gynecol. 36, 758–772 (1970).
    CAS PubMed Google Scholar
22. Capon, D.J. et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 337, 525–531 (1989).
    Article CAS PubMed Google Scholar
23. Finnerty, H. et al. Molecular cloning of murine FLT and FLT4. Oncogene 8, 2293–2298 (1993).
    CAS PubMed Google Scholar
24. Lucas, B.K. et al. High-level production of recombinant proteins using dicistronic DHFR into expression vector. Nucleic Acid Res. 24, 1774–1779 (1996).
25. Chisholm, V. High efficiency gene transfer into mammalian cells, in DNA Cloning 4: A Practical Approach, Mammalian systems,(eds. Glover, D.M. & Hames, B.D.) 1–39 (Oxford University Press, New York 1995).
    Google Scholar

Download references